Selection of large and objectively measurable target lesions in EORTC phase II trials: Impact on recruitment and response rate
- 31 December 1993
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (14) , 1943-1947
- https://doi.org/10.1016/0959-8049(93)90449-p
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Journal of Clinical Oncology, 1993
- Phase II studies: Wrong doses, wrong patients?European Journal of Cancer and Clinical Oncology, 1991
- EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agentsEuropean Journal of Cancer and Clinical Oncology, 1991
- Criteria of tumor response used in clinical trials of chemotherapy.Journal of Clinical Oncology, 1985
- Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.Journal of Clinical Oncology, 1984
- The effect of measuring error on the results of therapeutic trials in advanced cancerCancer, 1976